Filter
1493
Text search:
advanced
HIV
Featured
176
401
Language
Document type
846
222
216
85
54
33
20
6
6
1
1
1
1
Countries / Regions
72
67
62
54
45
34
31
31
30
28
26
26
26
25
19
18
17
16
15
15
14
14
13
13
11
11
10
10
10
9
8
7
7
7
7
7
6
5
5
4
4
4
4
4
3
3
3
3
2
2
2
2
2
2
2
2
2
2
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
Authors & Publishers
Publication Years
Category
622
173
97
66
54
47
20
2
Toolboxes
202
152
73
62
45
39
37
32
29
27
23
21
21
19
19
19
12
9
8
5
5
4
4
2
1
Vision Statement
From birth to 8 years of age, all children of the Republic of the Union of Myanmar will receive holistic, high-quality and developmentally-appropriate care from their parents, caregivers and service providers to ensure they will be happy, healthy, well nourished, socially adept ...
From birth to 8 years of age, all children of the Republic of the Union of Myanmar will receive holistic, high-quality and developmentally-appropriate care from their parents, caregivers and service providers to ensure they will be happy, healthy, well nourished, socially adept ...
This document contains: The systematic reviews and GRADE assessments used at the Index-TB Guideline Panel in July 2015; The Evidence to Decision tables that record the Panel’s assessment and recommendations from
this meeting
nterim guidance, first issued 25 January 2021, updated 15 June 2021, updated 19 November 2021, updated 23 February 2022, updated 18 August 2022
These WHO interim recommendations on the use of the Astra Zeneca – Oxford University AZD1222 vaccine against Covid-19 were developed on the basis of advice issued by the Strategic Advisory Group of Experts on Immunization (SAGE) and the evidence summary included in the background document referenc
...
6 June 2022
These WHO interim recommendations on the use of the Janssen Ad26.COV2.S (COVID-19) vaccine were developed on the basis of advice issued by the Strategic Advisory Group of Experts on Immunization (SAGE) and the evidence summary included in the background document referenced below.
Th
...
Interim recommendations for use of the inactivated COVID-19 vaccine, CoronaVac, developed by Sinovac
These WHO interim recommendations for use of the Sinovac-CoronaVac were developed on the basis of advice issued by the Strategic Advisory Group of Experts on Immunization (SAGE) and the evidence summary included in the background document and annexes referenced below.
This document has been updat
...
5 May 2021
This Information Note is intended to assist national TB programmes and health personnel worldwide to maintain essential tuberculosis (TB) services during the COVID-19 pandemic and in the recovery phase. It is important that recent progress made in TB prevention and care is not reversed b
...
These WHO interim recommendations for use of the BBV152 COVAXIN vaccine were developed on the basis of advice issued by the Strategic Advisory Group of Experts on Immunization (SAGE) and the evidence summary included in the background document and annexes referenced below.
This document has been
...
These WHO interim recommendations for use of the COVID-19 vaccine BIBP produced by Sinopharm were developed on the basis of advice issued by the Strategic Advisory Group of Experts on Immunization (SAGE) and the evidence summary included in the background document and annexes referenced below.
Th
...
an approach to optimize the global impact of COVID-19 vaccines, based on public health goals, global and national equity, and vaccine access and coverage scenarios, first issued 20 October 2020, updated: 13 November 2020, updated: 16 July 2021, latest update: 21 January 2022
Available in English, F
...
This report presents an analysis of antibacterial agents in preclinical (third annual review) and clinical (fifth annual review) development. The analysis covers traditional (direct-acting small molecules) and non-traditional antibacterial agents in development worldwide. It evaluates to what extent
...
The Practical manual on laboratory strengthening, 2022 update provides practical guidance on implementation of WHO recommendations and best practices for TB laboratory strengthening. It is an updated version of the GLI Practical Guide to Laboratory Strengthening published in 2017 and provides the la
...
Mpox continues to affect people around the world. A new framework released today by WHO will guide health authorities, communities and other stakeholders in preventing and controlling mpox outbreaks, eliminating human-to-human transmission of the disease, and reducing spillover of the virus from ani
...
interim guidance, 25 November 2024
The guidelines are primarily intended for health-care professionals working in first- or second-level health-care facilities, including emergency, inpatient and outpatient services. They are also directed at policy-makers, health-care planners and programme managers, academic institutions, non-gover
...
In line with the Defeating meningitis by 2030: a global road map, the WHO guidelines on meningitis diagnosis, treatment and care Executive Summary provides a summary of the evidence-based recommendations for the clinical management of children and adults with community-acquired meningitis, including
...
This resulting toolkit is a practical guide intended to assist users to become advocates for palliative care in a practical and effective
way. It is not necessarily a resource to read from cover to cover; rather, it can also be used selectively to each reader’s needs to engage audiences and
...
The WHO publication “Surveillance, case investigation and contact tracing for mpox: interim guidance” provides updated global technical guidance on monitoring and responding to mpox (formerly known as monkeypox). It explains how countries should conduct surveillance to detect new outbreaks, car
...
